A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy With or Without Bevacizumab in Patients With Advanced Solid Tumours

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04421820

Title field or adapter rule

{'original_value': 'A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy With or Without Bevacizumab in Patients With Advanced Solid Tumours', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:21.651475+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-10-31T22:18:28.651351+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Colorectal Cancer", "Pancreatic Cancer", "Gastric Cancers", "Cholangiocarcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT04421820"

protocolSection.identificationModule.officialTitle

"A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy With or Without Bevacizumab in Patients With Advanced Solid Tumours"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Colorectal Cancer (protocolSection.conditionsModule.conditions)
• Pancreatic Cancer (protocolSection.conditionsModule.conditions)
• Gastric Cancers (protocolSection.conditionsModule.conditions)
• Cholangiocarcinoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Part B - Dose Expansion - 2L Colorectal Cancer (ARM VIIA)', 'Part B - Dose Expansion - 2L Colorectal Cancer (ARM VIIB)', 'Part B - Dose Expansion - 2L Colorectal Cancer (ARM VIIC)'], 'description': 'Arm VIIA: 500 mg/m2 BOLD-100 combined with FOLFOX ± Bevacizumab; Arm VIIB: 625 mg/m2 BOLD-100 combined with FOLFOX ± Bevacizumab; Arm VIIC: FOLFOX ± Bevacizumab alone', 'name': 'BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part B - Dose Expansion - 1L Gastric Cancer (ARM I)', 'Part B - Dose Expansion - 2L Cholangiocarcinoma (ARM V)', 'Part B - Dose Expansion - 2L Colorectal Cancer (ARM IV)', 'Part B - Dose Expansion - 2L Gastric Cancer (ARM II)', 'Part B - Dose Expansion - 2L Pancreatic Cancer (ARM III)', 'Part B - Dose Expansion - 3L Colorectal Cancer (ARM VI)'], 'description': 'BOLD-100 at 625 mg/m2 combined with FOLFOX Chemotherapy', 'name': 'BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII) (protocolSection.armsInterventionsModule.interventions[].name)
• BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI) (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.